Ilaris

Phase 2Biologic

Novartis

Ilaris is one of 4 biologic programs targeting Schnitzler syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Schnitzler SyndromeActive, not recruiting

Schnitzler SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Schnitzler Syndrome

#DrugCompanyPhaseTrials

Ilaris

Novartis

Phase 2

2 2

Actemra

RPH-104

1 4

Ilaris

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Recruiting

Study completion

NCT06838143

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease

Completed·AAO GENERIUM·Phase 3·NCT06497491·118 enrolled

Tics1 trial

A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy Volunteers

Completed·AAO GENERIUM·Phase 1·NCT06481189·105 enrolled

Schnitzler syndrome1 trial

Ilaris (Canakinumab) in the Schnitzler Syndrome

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT01245127·1 enrolled

Unspecified1 trial

Ilaris NIS in Korea

Recruiting· Novartis logo

Novartis··NCT06838143·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ilaris. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ilaris compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ilaris. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Novartis

Ilaris

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Efficacy and Safety1 trial

Tics1 trial

Schnitzler syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News